A number of other research analysts have also weighed in on the company. BidaskClub lowered BeiGene from a strong-buy rating to a buy rating in a report on Wednesday, June 13th. Zacks Investment Research upgraded BeiGene from a sell rating to a hold rating in a report on Wednesday, June 13th. ValuEngine upgraded BeiGene from a hold rating to a buy rating in a report on Friday, June 1st. Maxim Group raised their price objective on BeiGene from $200.00 to $225.00 and gave the company a buy rating in a report on Friday, May 18th. Finally, Credit Suisse Group assumed coverage on BeiGene in a report on Monday, May 14th. They issued an outperform rating on the stock. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $173.00.
Shares of BeiGene opened at $168.49 on Friday, Marketbeat reports. The company has a debt-to-equity ratio of 0.12, a quick ratio of 11.12 and a current ratio of 11.18. The firm has a market capitalization of $9.06 billion, a price-to-earnings ratio of -75.56 and a beta of 0.36. BeiGene has a fifty-two week low of $38.14 and a fifty-two week high of $220.10.
Several institutional investors and hedge funds have recently modified their holdings of BGNE. Tower Research Capital LLC TRC acquired a new stake in shares of BeiGene in the 4th quarter worth $182,000. Comerica Bank acquired a new stake in shares of BeiGene in the 4th quarter worth $246,000. Mackenzie Financial Corp acquired a new stake in shares of BeiGene in the 4th quarter worth $250,000. Jefferies Group LLC acquired a new stake in shares of BeiGene in the 4th quarter worth $283,000. Finally, Quantbot Technologies LP acquired a new stake in shares of BeiGene in the 1st quarter worth $290,000. 67.15% of the stock is owned by institutional investors and hedge funds.
BeiGene Company Profile
BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.